How Analysts View Stericycle After Earnings

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
How Analysts View Stericycle After Earnings

© Thinkstock

Stericycle Inc. (NASDAQ: SRCL) reported its first-quarter financial results after the markets closed on Thursday. Unfortunately, the results missed earnings expectations and the stock saw a new 52-week low early in Friday’s session. As a result, a few analysts poured into the stock.

The company said it had $1.11 in earnings per share (EPS) on $874 million in revenue, compared to consensus estimates of $1.15 in EPS on revenue of $873.6 million. In the same period of last year, it posted EPS of $1.15 and $663.3 million in revenue.

Cash flow from operations was $156.9 million for the first quarter. On the books, cash, cash equivalents and short-term investments totaled $45.72 million, compared to $55.70 million at the end of 2015.

So far in 2016, Stericycle has performed relatively flat, with shares up about 1% year to date, prior to Friday’s move. Over the past 52 weeks, the stock is down 9%.
[nativounit]
A few analysts weighed in on the stock just after the earnings report:

  • Stifel downgraded it to a Hold rating from Buy.
  • RBC Capital Markets downgraded it to Underperform from Sector Perform and lowered its price target to $96 from $119.
  • Jefferies maintained a Buy rating but the price target was lowered to $140 from $146.
  • Baird has a Neutral rating and lowered its price target to $115 from $129.
  • Goldman Sachs has a Neutral rating and lowered its price target from $127 to $111.
  • Raymond James downgraded it to Market Perform from Outperform.
  • Stifel downgraded it to a Hold rating from Buy.

Shares of Stericycle were trading down more than 20% at $96.74 on Friday, with a consensus analyst price target of $137.55 and a 52-week trading range of $91.05 to $151.57.

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618